Abuse-deterrent formulations: part 1 – development of a formulation-based classification system

Bibliography

• Sapienza FL. Abuse deterrent formulations and the Controlled Substances Act (CSA). Drug Alcohol Depend 2006;83(Suppl 1):S23–30
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I--evidence assessment. Pain Physician 2012;15(3):S1–65
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Opioid painkiller prescribing: where you live makes a difference. CDC Vital Signs. 2014. Available from: www.cdc.gov/vitalsigns/opioid-prescribing/ [Last accessed 15 September 2014]
   Google Scholar
• Substance abuse and mental health services administration. Results from the 2012 national survey on drug use and health: summary of national findings. NSDUH Series H-46, HHS publication no. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2013
   Google Scholar
• Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2013;39(5):611–24
   PubMed Web of Science ®Google Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011;37(4):205–17
   PubMed Web of Science ®Google Scholar
• Omidian H, Mastropietro DJ. Fighting a new drug epidemic. J Develop Drugs 2013;2(1):1000e120
   Google Scholar
• Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(Suppl 2):S124–33
   PubMed Web of Science ®Google Scholar
• Passik SD. Tamper-resistant opioid formulations in the treatment of acute pain. Adv Ther 2014;31(3):264–75
   PubMed Web of Science ®Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010;24(10):805–10
   PubMed Web of Science ®Google Scholar
• Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P & T : a peer-reviewed journal for formulary management 2012;37(7):412–18
   PubMedGoogle Scholar
• Bartholomaus J, Kugelmann H, Arkenau-Maric E. inventors; Abuse-proofed dosage form. US8309060; 2012
   Google Scholar
• Habib W, Hamed E, Vega Zepeda MA. inventors; Abuse resistant drug formulation. US8445018; 2013
   Google Scholar
• Bastin RJ, Lithgow BH. inventors; Aventis Pharma Limited, assignee. Abuse resistant tablets. US6309668; 2001
   Google Scholar
• Matthews F, Boehm G, Tang L, Liang A. inventors; Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist. US8158156; 2012
   Google Scholar
• Yum SuII, Schoenhard G, Tipton AJ, inventors; Oral drug delivery system. US8420120; 2013
   Google Scholar
• Mastropietro D, Muppalaneni S, Kariman A, Omidian H. Shear-thinning rheology of the abuse-deterrent dosage form extracts. J Develop Drugs 2013;2(3):1–3
   Google Scholar
• Soscia AE, Peng Y, Sun Y, inventors; Dosage forms for tamper prone therapeutic agents. US8349362; 2013
   Google Scholar
• Chang RK. inventor Less abusable pharmaceutical preparations. U.S. Patent Application No 2006/0083690; 2006
   Google Scholar
• Abreu O. inventor Tamper resistant dosage form comprising an adsorbent and an adverse agent. US8298579; 2012
   Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN pharmaceutics 2012;2012:195727
   PubMedGoogle Scholar
• Vinson R, Gosseling P, Betancourt AO. inventors; Narcotic drug formulations with decreased abuse potential. US8460640; 2013
   Google Scholar
• Brzeczko AW, Hollenbeck RG. inventors; Methods and compositions for self-regulated release of active pharmacetical ingredient. U.S. Patent Application No 2014/0155388; 2014
   Google Scholar
• Clinical Pharmacology [database online]. Gold Standard, Inc, naloxone monograph. 2013. Available from: www.clinicalpharmacology.com/ [Last accessed 20 Febraury 2014]
   Google Scholar
• Passik SD. Issues in Long-term Opioid Therapy: unmet Needs, Risks, and Solutions. Mayo Clin Proc 2009;84(7):593–601
   PubMed Web of Science ®Google Scholar
• Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag 2010;6(4):300–3
   PubMedGoogle Scholar
• Pfizer Inc. EMBEDA®Important information for patients and prescribers. Available from: http://embeda.com/ [Last accessed 20 Febraury 2014]
   Google Scholar
• Stinchcomb AL, Golinski MJ, Hammell DC, Howard JL. inventors; Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs. US7511054; 2009
   Google Scholar
• Mickle T, Krishman S, Moncrief JS, et al. inventors Abuse-resistant hydrocodone compounds. US7375082; 2008
   Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc 2009;84(7):613–24
   PubMed Web of Science ®Google Scholar
• Monte AA, Heard KJ, Campbell J, et al. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med 2014;21(8):879–85
   PubMed Web of Science ®Google Scholar
• Bear D. inventor Material for controlling diversion of medications. US7226619; 2007
   Google Scholar
• Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors; Acura Pharmaceuticals, Inc, assignee. Methods and compositions for deterring abuse of opioid containing dosage forms. US7201920; 2007
   Google Scholar
• Sackler R. inventor; Tamper Resistant solid oral dosage forms. U.S. Patent Application No 2014/0010874; 2014
   Google Scholar
• Oshlack B, Colucci RD, Wright C, Breder C. inventors; Pharmaceutical formulation containing bittering agent. US7141250; 2006
   Google Scholar
• Frank ME, Bouverat BP, MacKinnon BI, Hettinger TP. The distinctiveness of ionic and nonionic bitter stimuli. Physiol Behav 2004;80(4):421–31
   PubMed Web of Science ®Google Scholar
• European medicines agency. Committee for medicinal products for human use (CHMP). Guideline on clinical development of fixed combination medicinal products. CHMP/EWP/240/95. European medicines agency, London, UK; 2009
   Google Scholar
• Diezi TA, Park JH, Raman SN. inventors; immediate release pharmaceutical compositions with abuse deterrent properties. U.S. Patent Application No 2013/0280176; 2013
   Google Scholar
• Boehm G. inventor; Sequestering subunit and related compositions and methods. US8685443; 2014
   Google Scholar
• Martinez A, Rougeot O, Yaguchi Y. inventors; Pharmaceutical composition for oral administration intended to prevent misue. U.S. Patent Application No 2013/0280326; 2013
   Google Scholar
• Marcenyac G, Alfonso M, Gehrlein L, et al. Greenbaum R, et al., inventors; Disposal system for transdermal dosage form. U.S. Patent Application No 2008/0262284; 2008
   Google Scholar
• Goldberg AP. inventor; Transdermal delivery form disposal systems and methods. U.S. patent application no 12/048771; 2008
   Google Scholar
• Tavares L, Reidenberg BE, Sackler R, et al. inventors; Abuse resistant opioid containing transdermal systems. U.S. Patent Application No 2004/0241218; 2004
   Google Scholar
• U.S. Food and Drug Administration. FDA approves abuse-deterrent labeling for reformulated OxyContin. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm [Last accessed 31 March 2014]
   Google Scholar
• Comer SD, Zacny JP, Dworkin RH, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 2012;153(12):2315–24
   PubMed Web of Science ®Google Scholar
• Title 21 United states code. § 321. US Code - Section 321: Definitions; generally
   Google Scholar
• Code of Federal Regulations. 21 CFR 201.56 Part 201: labeling. US Food and Drug Administration, Silver Springs, MD; 2012
   Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351–8
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367(2):187–9
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Commercial abuse-deterrent dosage forms: clinical status. J Develop Drugs 2013;2(103):1–6
   Google Scholar
• Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend 2013;131(1-2):100–5
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (Draft) Guidance for industry, abuse-deterrent opioids-evaluation and labeling. 2013. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf [Last accessed 24 March 2014]
   Google Scholar